CONTACT
+91 80 2808 2808
info@biocon.com

Press Releases

Biocon  /  News – Posts  /  Press Releases

Biocon Announces Exclusive Global Collaboration with Sandoz on Next-Generation Biosimilars
  • Thu, 18-Jan-2018
  • Posted by: BIOCON
No Comments

Biocon and Mylan’s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs
  • Fri, 29-Dec-2017
  • Posted by: BIOCON
No Comments

U.S. FDA Approves Mylan and Biocon´s OgivriTM the First Biosimilar for Trastuzumab, for the Treatment of HER2­Positive Breast and Gastric Cancers
  • Fri, 01-Dec-2017
  • Posted by: BIOCON
No Comments

European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon´s Proposed Biosimilars Trastuzumab and Pegfilgrastim
  • Fri, 01-Dec-2017
  • Posted by: BIOCON
No Comments

Biocon Launches KRABEVA® − Biosimilar Bevacizumab for Treating Several Types of Cancer in India
  • Thu, 23-Nov-2017
  • Posted by: BIOCON
No Comments

Biocon Q2FY18 Revenues at Rs 1019 Crore; EBITDA at Rs 233 Crore; Net Profit at Rs 69 Crore
  • Thu, 26-Oct-2017
  • Posted by: BIOCON
No Comments

Biocon Ranked Among Top 10 Global Pharma & Biotech Employers
  • Wed, 25-Oct-2017
  • Posted by: BIOCON
No Comments

JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment
  • Wed, 06-Sep-2017
  • Posted by: BIOCON
No Comments

Biocon Reports Q1FY18 Revenue at Rs 988 Crore; EBITDA at Rs 246 Crore; Net Profit at Rs 81 Crore
  • Thu, 27-Jul-2017
  • Posted by: BIOCON
No Comments

FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon’s Proposed Biosimilar Trastuzumab
  • Fri, 14-Jul-2017
  • Posted by: BIOCON
No Comments

Report adverse event/ side effects and/or product complaints for Biocon products.


Click here to report adverse event/side effects/product complaints and/or submit medical queries for Biocon Biologics Limited & BBL Affiliate products.

Click here to report adverse event/side effects/product complaints and/or post medical queries for Biocon Limited, Biocon Pharma Limited, Biocon Pharma Inc., Biocon Pharma UK Limited, Biocon Pharma Malta Ltd and Biocon FZ LLC products.





* Safe Harbour | Privacy Policy | Terms of Use © 2024, Biocon. All Rights Reserved
Share
Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

Agree >>